Tinley Park, United States
Operating across the US, Europe, China, and Asia-Pacific, Hematogenix provides reference laboratory services, uniquely positioned to support clients in accelerating cancer research and drug development efforts across its globally connected facilities.
Services offered by Hematogenix include Flow Cytometry, Molecular Genetics, Next Generation Sequencing (NGS), Histology/Immunohistochemistry (IHC), Cytogenetics/FISH, Pathology, Digital Pathology, and Image Analysis, reflecting the company's commitment to utilizing advanced techniques to enhance patient care. The company also offers customized services from the initial stages of research to development, extending to the implementation of targeted therapies in the clinical setting. Furthermore, Hematogenix holds accreditations including CAP, CLIA certification, and GCP compliance, ensuring high-quality standards in its operations. Founded in 2007, Hematogenix operates within the pharmaceutical industry.
Currently, there is no publicly available information about Hematogenix's last investment or investors.
